{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:07:26Z","timestamp":1761584846015,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01GI1122G"],"award-info":[{"award-number":["01GI1122G"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis Supplements"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.atherosclerosissup.2012.10.010","type":"journal-article","created":{"date-parts":[[2013,1,26]],"date-time":"2013-01-26T12:34:16Z","timestamp":1359203656000},"page":"129-134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Lipoprotein apheresis reduces adipocyte fatty acid-binding protein serum levels"],"prefix":"10.1016","volume":"14","author":[{"given":"V.","family":"Lamounier-Zepter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Look","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ehrhart-Bornstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.R.","family":"Bornstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Julius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosissup.2012.10.010_bib1","doi-asserted-by":"crossref","first-page":"8683","DOI":"10.1021\/bi00448a003","article-title":"Human adipocyte lipid-binding protein: purification of the protein and cloning of its complementary DNA","volume":"28","author":"Baxa","year":"1989","journal-title":"Biochemistry"},{"key":"10.1016\/j.atherosclerosissup.2012.10.010_bib2","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/89076","article-title":"Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis","volume":"7","author":"Makowski","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.atherosclerosissup.2012.10.010_bib3","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1161\/CIRCRESAHA.109.200501","article-title":"Adipocyte fatty acid-binding protein suppresses cardiomyocyte contraction: a new link between obesity and heart disease","volume":"105","author":"Lamounier-Zepter","year":"2009","journal-title":"Circ Res"},{"key":"10.1016\/j.atherosclerosissup.2012.10.010_bib4","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1373\/clinchem.2005.062463","article-title":"Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome","volume":"52","author":"Xu","year":"2006","journal-title":"Clin Chem"},{"key":"10.1016\/j.atherosclerosissup.2012.10.010_bib5","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1043-2760(00)00257-5","article-title":"The mammalian fatty acid-binding protein multigene family: molecular and genetic insights into function","volume":"11","author":"Hertzel","year":"2000","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.atherosclerosissup.2012.10.010_bib6","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1126\/science.274.5291.1377","article-title":"Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein","volume":"274","author":"Hotamisligil","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.atherosclerosissup.2012.10.010_bib7","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1210\/endo.141.9.7637","article-title":"Improved glucose and lipid metabolism in genetically obese mice lacking aP2","volume":"141","author":"Uysal","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/j.atherosclerosissup.2012.10.010_bib8","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1161\/01.ATV.0000033090.81345.E6","article-title":"Adipocyte fatty acid-binding protein, aP2, alters late atherosclerotic lesion formation in severe hypercholesterolemia","volume":"22","author":"Boord","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosissup.2012.10.010_bib9","doi-asserted-by":"crossref","first-page":"6970","DOI":"10.1073\/pnas.0602178103","article-title":"A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease","volume":"103","author":"Tuncman","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.atherosclerosissup.2012.10.010_bib10","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/nature05844","article-title":"Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2","volume":"447","author":"Furuhashi","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosissup.2012.10.010_bib11","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1016\/j.bmcl.2004.06.057","article-title":"Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target","volume":"14","author":"Lehmann","year":"2004","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.atherosclerosissup.2012.10.010_bib12","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1016\/j.bmcl.2004.06.058","article-title":"Substituted benzylamino-6-(trifluoromethyl)pyrimidin-4(1H)-ones: a novel class of selective human A-FABP inhibitors","volume":"14","author":"Ringom","year":"2004","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.atherosclerosissup.2012.10.010_bib13","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00210-011-0667-1","article-title":"BMS309403 directly suppresses cardiac contractile function","volume":"384","author":"Look","year":"2011","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.atherosclerosissup.2012.10.010_bib14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.atherosclerosis.2006.02.030","article-title":"A systematic review of LDL apheresis in the treatment of cardiovascular disease","volume":"189","author":"Thompsen","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosissup.2012.10.010_bib15","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0002-9149(02)03248-4","article-title":"Effects of combined low-density lipoprotein apheresis and aggressive statin therapy on coronary calcified plaque as measured by computed tomography","volume":"91","author":"Hoffmann","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosissup.2012.10.010_bib16","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1161\/01.CIR.93.10.1826","article-title":"LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis","volume":"93","author":"Kroon","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosissup.2012.10.010_bib17","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0002-9149(98)00692-4","article-title":"Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group","volume":"82","author":"Mabuchi","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosissup.2012.10.010_bib18","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/j.1365-2362.1994.tb01068.x","volume":"24","author":"Schuff-Werner","year":"1994","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.atherosclerosissup.2012.10.010_bib19","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0002-9149(97)00947-8","article-title":"Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Liposorber Study Group","volume":"81","author":"Gordon","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosissup.2012.10.010_bib20","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/ijo.2008.128","article-title":"The increase of fatty acid-binding protein aP2 in overweight and obese children: interactions with dietary fat and impact on measures of subclinical inflammation","volume":"32","author":"Aeberli","year":"2008","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.atherosclerosissup.2012.10.010_bib21","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1046\/j.1526-0968.2002.00426.x","article-title":"First steps toward the establishment of a German low-density lipoprotein-apheresis registry: recommendations for the indication and for quality management","volume":"6","author":"Schettler","year":"2002","journal-title":"Ther Apher"},{"key":"10.1016\/j.atherosclerosissup.2012.10.010_bib22","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.106.647503","article-title":"Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study","volume":"115","author":"Xu","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosissup.2012.10.010_bib23","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1111\/j.1476-5381.2010.01158.x","article-title":"Chronic administration of BMS309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells","volume":"162","author":"Lee","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.atherosclerosissup.2012.10.010_bib24","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/00041433-199812000-00002","article-title":"Safety and effectiveness of long-term LDL-apheresis in patients at high risk","volume":"9","author":"Thiery","year":"1998","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.atherosclerosissup.2012.10.010_bib25","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1586\/14779072.6.5.629","article-title":"Comparison of different LDL apheresis methods","volume":"6","author":"Julius","year":"2008","journal-title":"Expert Rev Cardiovasc Ther"}],"container-title":["Atherosclerosis Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567568812000219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567568812000219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:01:24Z","timestamp":1761584484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567568812000219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S1567568812000219"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2012.10.010","relation":{},"ISSN":["1567-5688"],"issn-type":[{"type":"print","value":"1567-5688"}],"subject":[],"published":{"date-parts":[[2013,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipoprotein apheresis reduces adipocyte fatty acid-binding protein serum levels","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis Supplements","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2012.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}